Antifungal activity of [K3]temporin-SHa against medically relevant yeasts and moulds

被引:3
作者
Brunet, Kevin [1 ,2 ]
Verdon, Julien [2 ,3 ]
Ladram, Ali
Arnault, Simon [1 ]
Rodier, Marie-Helene [1 ,2 ,3 ]
Cateau, Estelle [2 ,3 ]
机构
[1] CHU Poitiers, Lab Parasitol & Mycol Med, Poitiers, France
[2] Univ Poitiers, Poitiers, France
[3] Univ Poitiers, Lab Ecol & Biol Interact, UMR CNRS 7267, Poitiers, France
关键词
antimicrobial peptides; Candida; K3]temporin-SHa; antifungal compound; TEMPORIN-L; SUSCEPTIBILITIES; MANAGEMENT; RESISTANCE; MECHANISMS; SKIN;
D O I
10.1139/cjm-2021-0250
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Few antifungal agents are currently available for the treatment of fungal infections. Antimicrobial peptides (AMPs), which are natural molecules involved in the innate immune response of many organisms, represent a promising research method because of their broad killing activity. The aim of this study was to assess the activity of a frog AMP, [K-3]temporin-SHa, against some species of yeasts and moulds, and to further explore its activity against Candida albicans. MIC determinations were performed according to EUCAST guidelines. Next, the activity of [K-3]temporin-SHa against C. albicans was explored using time-killing curve experiments, membrane permeabilization assays, and electron microscopy. Finally, chequerboard assays were performed to evaluate the synergy between [K-3]temporin-SHa and amphotericin B or fluconazole. [K-3]temporin-SHa was found to be active in vitro against several yeasts with MIC between 55 and 45 mu M. [K-3]temporin-SHa displayed rapid fungicidal activity against C. albicans (inoculum was divided into two in less than an hour and no viable colonies were recovered after 5 h) with a mechanism that could be due to membrane permeabilization. [K-3]temporin-SHa was synergistic with amphotericin B against C. albicans (FICI = 0.303). [K-3]temporin-SHa could represent an additional tool to treat several Candida species and C. neoformans.
引用
收藏
页码:427 / 434
页数:8
相关论文
共 37 条
  • [1] Isolation, characterization and molecular cloning of new temporins from the skin of the North African ranid Pelophylax saharica
    Abbassi, Feten
    Oury, Bruno
    Blasco, Thierry
    Sereno, Denis
    Bolbach, Gerard
    Nicolas, Pierre
    Hani, Khaled
    Amiche, Mohamed
    Ladram, Ali
    [J]. PEPTIDES, 2008, 29 (09) : 1526 - 1533
  • [2] Solution structure and model membrane interactions of temporins-SH, antimicrobial peptides from amphibian skin. A NMR spectroscopy and differential scanning calorimetry study
    Abbassi, Feten
    Galanth, Cecile
    Amiche, Mohamed
    Saito, Kazuko
    Piesse, Christophe
    Zargarian, Loussine
    Hani, Khaled
    Nicolas, Pierre
    Lequin, Olivier
    Ladram, Ali
    [J]. BIOCHEMISTRY, 2008, 47 (40) : 10513 - 10525
  • [3] Antibacterial and leishmanicidal activities of temporin-SHd, a 17-residue long membrane-damaging peptide
    Abbassi, Feten
    Raja, Zahid
    Oury, Bruno
    Gazanion, Elodie
    Piesse, Christophe
    Sereno, Denis
    Nicolas, Pierre
    Foulon, Thierry
    Ladram, Ali
    [J]. BIOCHIMIE, 2013, 95 (02) : 388 - 399
  • [4] Temporin-SHf, a New Type of Phe-rich and Hydrophobic Ultrashort Antimicrobial Peptide
    Abbassi, Feten
    Lequin, Olivier
    Piesse, Christophe
    Goasdoue, Nicole
    Foulon, Thierry
    Nicolas, Pierre
    Ladram, Ali
    [J]. JOURNAL OF BIOLOGICAL CHEMISTRY, 2010, 285 (22) : 16880 - 16892
  • [5] EUCAST technical note on isavuconazole breakpoints for Aspergillus, itraconazole breakpoints for Candida and updates for the antifungal susceptibility testing method documents
    Arendrup, M. C.
    Meletiadis, J.
    Mouton, J. W.
    Guinea, J.
    Cuenca-Estrella, M.
    Lagrou, K.
    Howard, S. J.
    [J]. CLINICAL MICROBIOLOGY AND INFECTION, 2016, 22 (06) : 571.e1 - 571.e4
  • [6] Update on antifungal resistance in Aspergillus and Candida
    Arendrup, M. C.
    [J]. CLINICAL MICROBIOLOGY AND INFECTION, 2014, 20 : 42 - 48
  • [7] Candida lusitaniae fungemia in cancer patients:: risk factors for amphotericin B failure and outcome
    Atkinson, Bradley J.
    Lewis, Russell E.
    Kontoyiannis, Dimitrios P.
    [J]. MEDICAL MYCOLOGY, 2008, 46 (06) : 541 - 546
  • [8] Antimicrobial Peptides and Nanotechnology, Recent Advances and Challenges
    Biswaro, Lubhandwa S.
    da Costa Sousa, Mauricio G.
    Rezende, Taia M. B.
    Dias, Simoni C.
    Franco, Octavio L.
    [J]. FRONTIERS IN MICROBIOLOGY, 2018, 9
  • [9] Bongomin F, 2017, J FUNGI, V3, DOI [10.3390/jof3020026, 10.3390/jof3040057]
  • [10] Candida Infections and Therapeutic Strategies: Mechanisms of Action for Traditional and Alternative Agents
    de Oliveira Santos, Giselle C.
    Vasconcelos, Cleydlenne C.
    Lopes, Alberto J. O.
    de Sousa Cartagenes, Maria Do S.
    Filho, Allan K. D. B.
    do Nascimento, Flavia R. F.
    Ramos, Ricardo M.
    Pires, Emygdia R. R. B.
    de Andrade, Marcelo S.
    Rocha, Flaviane M. G.
    Monteiro, Cristina de Andrade
    [J]. FRONTIERS IN MICROBIOLOGY, 2018, 9